American Journal of Clinical Dermatology

, Volume 9, Issue 4, pp 219–232

Imported Tropical Infectious Ulcers in Travelers

Review Article Imported Tropical Infectious Ulcers in Travelers

Abstract

Skin ulcers are a commonly encountered problem at departments of tropical dermatology in the Western world. Furthermore, the general dermatologist is likely to be consulted more often for imported chronic skin ulcers because of the ever-increasing travel to and from tropical countries. The most common cause of chronic ulceration throughout the world is probably pyoderma. However, in some parts of the world, cutaneous leishmaniasis is one of the most prevalent causes. Mycobacterium ulcerans is an important cause of chronic ulcers in West Africa.

Bacterial infections include pyoderma, mycobacterial infections, diphtheria, and anthrax. Pyoderma is caused by Staphylococcus aureus and/or β-hemolytic streptococci group A. This condition is a common cause of ulcerative skin lesions in tropical countries and is often encountered as a secondary infection in travelers. The diagnosis is often made on clinical grounds. Antibacterial treatment for pyoderma should preferably be based on culture outcome. Floxacillin is generally active against S. aureus and β-hemolytic streptococci. Infection with Mycobacterium ulcerans, M. marinum, and M. tuberculosis may cause ulcers. Buruli ulcers, which are caused by M. ulcerans, are endemic in foci in West Africa and have been reported as an imported disease in the Western world. Treatment is generally surgical, although a combination of rifampin (rifampicin) and streptomycin may be effective in the early stage. M. marinum causes occasional ulcerating lesions in humans. Treatment regimens consist of combinations containing clarithromycin, rifampin, or ethambutol. Cutaneous tuberculosis is rare in travelers but may be encountered in immigrants from developing countries. Treatment is with multiple drug regimens consisting of isoniazid, ethambutol, pyrazinamide, and rifampin. Cutaneous diphtheria is still endemic in many tropical countries. Cutaneous diphtheria ulcers are nonspecific and erythromycin and penicillin are both effective antibacterials. Antitoxin should be administered intramuscularly in suspected cases. Anthrax is caused by spore-forming Bacillus anthracis. This infection is still endemic in many tropical countries. Eschar formation, which sloughs and leaves behind a shallow ulcer at the site of inoculation, characterizes cutaneous anthrax. Penicillin and doxycycline are effective antibacterials.

Cutaneous leishmaniasis is caused by different species belonging to the genus Leishmania. The disorder is one of the ten most frequent causes of skin diseases in travelers returning from (sub)tropical countries. The clinical picture is diverse, ranging from a painless papule or nodule to an ulcer with or without a scab. Treatment depends on the clinical manifestations and the species involved.

Sporotrichosis, chromo(blasto)mycosis, and mycetoma are the most common mycoses that may be accompanied by ulceration. Infections are restricted to certain regions and often result from direct penetration of the fungus into the skin. Anti-mycotic treatment depends on the microorganism involved.

The most common causes of infectious skin ulceration encountered in patients from tropical countries who present at a department of tropical dermatology are reviewed in this article.

References

  1. 1.
    Ryan ET, Wilson ME, Kain KC. Illness after international travel. N Engl J Med 2002; 347: 505–16PubMedCrossRefGoogle Scholar
  2. 2.
    Wilson ME. Skin problems in the traveler. Infect Dis Clin North Am 1998; 12: 471–88PubMedCrossRefGoogle Scholar
  3. 3.
    Wilson ME, Chen LH. Dermatologic infectious diseases in international travelers. Curr Infect Dis Rep 2004; 6: 54–62PubMedCrossRefGoogle Scholar
  4. 4.
    Lucchina LC, Wilson ME, Drake LA. Dermatology and the recently returned traveler: infectious diseases with dermatologic manifestations. Int J Dermatol 1997; 36: 167–81PubMedCrossRefGoogle Scholar
  5. 5.
    Freedman DO, Weld LH, Kozarsky PE,et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006; 354: 119–30PubMedCrossRefGoogle Scholar
  6. 6.
    Zeegelaar JE, Steketee WH, van Thiel PP. Changing pattern of imported cutaneous leishmaniasis in the Netherlands. Clin Exp Dermatol 2005; 30: 1–5PubMedCrossRefGoogle Scholar
  7. 7.
    Lupi O, Madkan V, Tyring SK. Tropical dermatology: bacterial tropical diseases. J Am Acad Dermatol 2006; 54: 559–78PubMedCrossRefGoogle Scholar
  8. 8.
    Gupta SK, Shukla VK. Leg ulcers in the tropics. Int J Low Extrem Wounds 2002; 1: 58–61PubMedCrossRefGoogle Scholar
  9. 9.
    Oluwasanmi JO, Alao MO, Ofodile FA. Tropical ulcers. Plast Reconstr Surg 1979; 64: 41–6PubMedCrossRefGoogle Scholar
  10. 10.
    Maddox JS, Ware JC, Dillon Jr HC. The natural history of streptococcal skin infection: prevention with topical antibiotics. J Am Acad Dermatol 1985; 13: 207–12PubMedCrossRefGoogle Scholar
  11. 11.
    Greene SL, Su WP, Muller SA. Ecthyma gangrenosum: report of clinical, histopathologic, and bacteriologic aspects of eight cases. J Am Acad Dermatol 1984; 11: 781–7PubMedCrossRefGoogle Scholar
  12. 12.
    Dillon Jr HC. Post-streptococcal glomerulonephritis following pyoderma. Rev Infect Dis 1979; 1: 935–45PubMedCrossRefGoogle Scholar
  13. 13.
    Alausa OK, Montefiore D. Bacterial infections, sensitivity patterns, and chemotherapy among hospital patients in the tropics. Scand J Infect Dis 1978; 10: 295–302PubMedGoogle Scholar
  14. 14.
    Rotta J, Tikhomirov E. Streptococcal diseases worldwide: present status and prospects. Bull World Health Organ 1987; 65: 769–77PubMedGoogle Scholar
  15. 15.
    Mahe A, Prual A, Konate M,et al. Skin diseases of children in Mali: a public health problem. Trans R Soc Trop Med Hyg 1995; 89: 467–70PubMedCrossRefGoogle Scholar
  16. 16.
    Brahmadathan KN, Koshi G. Epidemiology of streptococcal pyoderma in an orphanage community of a tropical country. J Trop Med Hyg 1988; 91: 306–14PubMedGoogle Scholar
  17. 17.
    Caumes E, Carriere J, Guermonprez G,et al. Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit. Clin Infect Dis 1995; 20: 542–8PubMedCrossRefGoogle Scholar
  18. 18.
    Naafs B. Tropical holiday memories. Eur J Dermatol 1999; 9: 500–5PubMedGoogle Scholar
  19. 19.
    Brahmadathan KN, Koshi G. Importance of group G streptococci in human pyogenic infections. J Trop Med Hyg 1989; 92: 35–8PubMedGoogle Scholar
  20. 20.
    Suite M. Cutaneous infections in Trinidad. Int J Dermatol 1990; 29: 31–4PubMedCrossRefGoogle Scholar
  21. 21.
    Allen AM, Taplin D, Twigg L. Cutaneous streptococcal infections in Vietnam. Arch Dermatol 1971; 104: 271–80PubMedCrossRefGoogle Scholar
  22. 22.
    Sheagren JN. Staphylococcal infections of the skin and skin structures. Cutis 1985; 36: 2–6PubMedGoogle Scholar
  23. 23.
    Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334: 240–5PubMedCrossRefGoogle Scholar
  24. 24.
    Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520–32PubMedCrossRefGoogle Scholar
  25. 25.
    Martin JM, Green M. Group A streptococcus. Semin Pediatr Infect Dis 2006; 17: 140–8PubMedCrossRefGoogle Scholar
  26. 26.
    Basak S, Dutta SK, Gupta S,et al. Bacteriology of wound infection: evaluation by surface swab and quantitative full thickness wound biopsy culture. J Indian Med Assoc 1992; 90: 33–4PubMedGoogle Scholar
  27. 27.
    Slater RA, Lazarovitch T, Boldur I,et al.Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med 2004; 21: 705–9PubMedCrossRefGoogle Scholar
  28. 28.
    Bill TJ, Ratliff CR, Donovan AM,et al. Quantitative swab culture versus tissue biopsy: a comparison in chronic wounds. Ostomy Wound Manage 2001; 47: 34–7PubMedGoogle Scholar
  29. 29.
    Perry CR, Pearson RL, Miller GA. Accuracy of cultures of material from swabbing of the superficial aspect of the wound and needle biopsy in the preoperative assessment of osteomyelitis. J Bone Joint Surg Am 1991; 73: 745–9PubMedGoogle Scholar
  30. 30.
    Nagaraju U, Bhat G, Kuruvila M,et al. Methicillin-resistant Staphylococcus aureus in community acquired pyoderma. Int J Dermatol 2004; 43: 412–4PubMedCrossRefGoogle Scholar
  31. 31.
    Zeegelaar IE, Langenberg W, Hu R,et al. Tolerability and efficacy of hydrocolloid dressings in the treatment of venous leg ulcers under tropical conditions: an open prospective study. J Eur Acad Dermatol Venereol 2001; 15: 234–7PubMedCrossRefGoogle Scholar
  32. 32.
    Price JD, Harding JW. Flucloxacillin in the treatment of infectious conditions in children. Curr Med Res Opin 1975; 3: 77–82PubMedCrossRefGoogle Scholar
  33. 33.
    Duncan JT. A clinical appraisal of flucloxacillin in the management of skin and soft tissue infections in Nigeria. J Int Med Res 1984; 12: 210–5PubMedGoogle Scholar
  34. 34.
    Crofts HG. Flucloxacillin (Floxapen) in the treatment of skin and upper respiratory tract infections. N Z Med J 1978; 87: 308–11PubMedGoogle Scholar
  35. 35.
    Korting HC, Neubert U, Abeck D. Current antimicrobial susceptibility of cutaneous bacteria to firstline antibiotics. Int J Antimicrob Agents 1998; 10: 165–8PubMedCrossRefGoogle Scholar
  36. 36.
    Moellering JrRC. Past, present, and future of antimicrobial agents. Am J Med 1995; 99: 11–8SCrossRefGoogle Scholar
  37. 37.
    Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003; 63: 1459–80PubMedCrossRefGoogle Scholar
  38. 38.
    Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 565–7Google Scholar
  39. 39.
    Winter GD, Scales JT. Effect of air drying and dressings on the surface of a wound. Nature 1963; 197: 91–2PubMedCrossRefGoogle Scholar
  40. 40.
    Hautmann G, Lotti T. Atypical mycobacterial infections of the skin. Dermatol Cli 1994; 12: 657–68Google Scholar
  41. 41.
    Kostman JR, DiNubile MJ. Nodular lymphangitis: a distinctive but often unrecognized syndrome. Ann Intern Med 1993; 118: 883–8PubMedGoogle Scholar
  42. 42.
    van der Werf TS, van der Graaf WT, Tappero JW,. Mycobacterium ulcerans infection. Lancet 1999; 354: 1013–8PubMedCrossRefGoogle Scholar
  43. 43.
    Dodiuk-Gad R, Dyachenko P, Ziv M, et al. Nontuberculous mycobacterial infections of the skin: a retrospective study of 25 cases. J Am Acad Dermatol 2007; 57 (3): 413–20PubMedCrossRefGoogle Scholar
  44. 44.
    Portaels F. Epidemiology of mycobacterial diseases. Clin Dermatol 1995; 13: 207–22PubMedCrossRefGoogle Scholar
  45. 45.
    Wayne LG, Sramek HA. Agents of newly recognized or infrequently encountered mycobacterial diseases. Clin Microbiol Rev 1992; 5: 1–25PubMedGoogle Scholar
  46. 46.
    Street ML, Umbert-Millet IJ, Roberts GD,et al. Nontuberculous mycobacterial infections of the skin: report of fourteen cases and review of the literature. J Am Acad Dermatol 1991; 24: 208–15PubMedCrossRefGoogle Scholar
  47. 47.
    Clancey JK. Mycobacterial skin ulcers in Uganda: description of a new mycobacterium (Mycobacterium buruli). J Pathol Bacteriol 1964; 88: 175–87PubMedCrossRefGoogle Scholar
  48. 48.
    Portaels F, Chemlal K, Elsen P,et al. Mycobacterium ulcerans in wild animals. Rev Sci Tech 2001; 20: 252–64PubMedGoogle Scholar
  49. 49.
    Eddyani M, Ofori-Adjei D, Teugels G,et al. Potential role for fish in transmission of Mycobacterium ulcerans disease (Buruli ulcer): an environmental study. Appl Environ Microbiol 2004; 70: 5679–81PubMedCrossRefGoogle Scholar
  50. 50.
    Portaels F, Elsen P, Guimaraes-Peres A, et al. Insects in the transmission of Mycobacterium ulcerans infection [letter]. Lancet 1999; 353: 986PubMedCrossRefGoogle Scholar
  51. 51.
    Marston BJ, Diallo MO, Horsburgh Jr CR, et al. Emergence of Buruli ulcer disease in the Daloa region of Cote d’Ivoire. Am J Trop Med Hyg 1995; 52: 219–24PubMedGoogle Scholar
  52. 52.
    Debacker M, Aguiar J, Steunou C, et al. Buruli ulcer recurrence, Benin. Emerg Infect Dis 2005; 11: 584–9PubMedCrossRefGoogle Scholar
  53. 53.
    Amofah G, Bonsu F, Tetteh C, et al. Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis 2002; 8: 167–70PubMedCrossRefGoogle Scholar
  54. 54.
    Barker DJ. Epidemiology of Mycobacterium ulcerans infection. Trans R Soc Trop Med Hyg 1973; 67: 43–50PubMedCrossRefGoogle Scholar
  55. 55.
    Semret M, Koromihis G, MacLean JD,et al. Mycobacterium ulcerans infection (Buruli ulcer): first reported case in a traveler. Am J Trop Med Hyg 1999; 61: 689–93PubMedGoogle Scholar
  56. 56.
    Faber WR, Arias-Bouda LM, Zeegelaar JE,et al. First reported case of Mycobacterium ulcerans infection in a patient from China. Trans R Soc Trop Med Hyg 2000; 94: 277–9PubMedCrossRefGoogle Scholar
  57. 57.
    Evans MR, Mawdsley J, Bull R,et al. Buruli ulcer in a visitor to London. Br J Dermatol 2003; 149: 907–9PubMedCrossRefGoogle Scholar
  58. 58.
    Ross BC, Johnson PD, Oppedisano F, et al. Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Appl Environ Microbiol 1997; 63: 4135–8PubMedGoogle Scholar
  59. 59.
    Portaels F, Meyers WM. Buruli ulcer. In: Faber WR, Hay RJ, Naafs B, editors. Imported skin diseases. Maarssen: Elsevier, 2006Google Scholar
  60. 60.
    Hayman J. Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. J Clin Pathol 1993; 46: 5–9PubMedCrossRefGoogle Scholar
  61. 61.
    Meyers WM, Shelly WM, Connor DH. Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am J Trop Med Hyg 1974; 23: 924–9PubMedGoogle Scholar
  62. 62.
    Palomino JC, Obiang AM, Realini L,et al. Effect of oxygen on growth of Mycobacterium ulcerans in the BACTEC system. J Clin Microbiol 1998; 36: 3420–2PubMedGoogle Scholar
  63. 63.
    Roberts B, Hirst R. Immunomagnetic separation and PCR for detection of Mycobacterium ulcerans. J Clin Microbiol 1997; 35: 2709–11PubMedGoogle Scholar
  64. 64.
    Ross BC, Marino L, Oppedisano F, et al. Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol 1997; 35: 1696–700PubMedGoogle Scholar
  65. 65.
    Stienstra Y, van der Werf TS, Guarner J,et al. Analysis of an IS2404-based nested PCR for diagnosis of Buruli ulcer disease in regions of Ghana where the disease is endemic. J Clin Microbiol 2003; 41: 794–7PubMedCrossRefGoogle Scholar
  66. 66.
    Buruli ulcer disease. Wkly Epidemiol Rec 2004; 79: 194–9Google Scholar
  67. 67.
    Dega H, Bentoucha A, Robert J,et al. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 2002; 46: 3193–6PubMedCrossRefGoogle Scholar
  68. 68.
    Gluckman SJ. Mycobacterium marinum. Clin Dermatol 1995; 13: 273–6PubMedCrossRefGoogle Scholar
  69. 69.
    Lewis FM, Marsh BJ, von Reyn CF. Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin Infect Dis 2003; 37: 390–7PubMedCrossRefGoogle Scholar
  70. 70.
    Chemlal K, Portaels F. Molecular diagnosis of nontuberculous mycobacteria. Curr Opin Infect Dis 2003; 16: 77–83PubMedCrossRefGoogle Scholar
  71. 71.
    Bayer-Garner IB, Cox MD, Scott MA,et al. Mycobacteria other than Mycobacterium tuberculosis are not present in erythema induratum/nodular vasculitis: a case series and literature review of the clinical and histologic findings. J Cutan Pathol 2005; 32: 220–6PubMedCrossRefGoogle Scholar
  72. 72.
    Braback M, Riesbeck K, Forsgren A. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones. Antimicrob Agents Chemother 2002; 46: 1114–6PubMedCrossRefGoogle Scholar
  73. 73.
    Gimenez GR, Sanchez RS, Iban Ochoa RM, et al. Fish tank granuloma: response to treatment with clarithromycin. J Eur Acad Dermatol Venereol 1999; 12: 81–2Google Scholar
  74. 74.
    Yates VM, Ormerod LP. Cutaneous tuberculosis in Blackburn district (U.K.): a 15-year prospective series, 1981-95. Br J Dermatol 1997; 136: 483–9PubMedCrossRefGoogle Scholar
  75. 75.
    Beutner EH. Tuberculosis of the skin: historical perspectives on tuberculin and Bacille Calmette Guerin. Int J Dermatol 1997; 36: 73–7PubMedCrossRefGoogle Scholar
  76. 76.
    MacGregor RR. Cutaneous tuberculosis. Clin Dermatol 1995; 13: 245–55PubMedCrossRefGoogle Scholar
  77. 77.
    Barbagallo J, Tager P, Ingleton R,et al. Cutaneous tuberculosis: diagnosis and treatment. Am J Clin Dermatol 2002; 3: 319–28PubMedCrossRefGoogle Scholar
  78. 78.
    Seckin D, Akpolat T, Ceyhan M,et al. Polymerase chain reaction in cutaneous tuberculosis. Int J Dermatol 1997; 36: 51–4PubMedCrossRefGoogle Scholar
  79. 79.
    Hofler W. Cutaneous diphtheria. Int J Dermatol 1991; 30: 845–7PubMedCrossRefGoogle Scholar
  80. 80.
    Wagner J, Ignatius R, Voss S, et al. Infection of the skin caused by Corynebacterium ulcerans and mimicking classical cutaneous diphtheria. Clin Infect Dis 2001; 33: 1598–600PubMedCrossRefGoogle Scholar
  81. 81.
    Pandit N, Yeshwanth M. Cutaneous diphtheria in a child. Int J Dermatol 1999; 38: 298–9PubMedCrossRefGoogle Scholar
  82. 82.
    Koopman JS, Campbell J. The role of cutaneous diphtheria infections in a diphtheria epidemic. J Infect Dis 1975; 131: 239–44PubMedCrossRefGoogle Scholar
  83. 83.
    Kjeldsen K, Simonsen O, Heron I. Immunity against diphtheria 25-30 years after primary vaccination in childhood. Lancet 1985; I: 900–2CrossRefGoogle Scholar
  84. 84.
    de Benoist AC, White JM, Efstratiou A,et al. Imported cutaneous diphtheria, United Kingdom. Emerg Infect Dis 2004; 10: 511–3PubMedCrossRefGoogle Scholar
  85. 85.
    Van den Enden E, Van Gompel A, Van Esbroeck M. Cutaneous anthrax, Belgian traveler. Emerg Infect Dis 2006; 12: 523–5PubMedCrossRefGoogle Scholar
  86. 86.
    Swartz MN. Recognition and management of anthrax: an update. N Engl J Med 2001; 345: 1621–6PubMedCrossRefGoogle Scholar
  87. 87.
    Dixon TC, Meselson M, Guillemin J,et al. Anthrax. N Engl J Med 1999; 341: 815–26PubMedCrossRefGoogle Scholar
  88. 88.
    Sternbach G. The history of anthrax. J Emerg Med 2003; 24: 463–7PubMedCrossRefGoogle Scholar
  89. 89.
    Shlyakhov E, Rubinstein E. Evaluation of the anthraxin skin test for diagnosis of acute and past human anthrax. Eur J Clin Microbiol Infect Dis 1996; 15: 242–5PubMedCrossRefGoogle Scholar
  90. 90.
    Desjeux P. Leishmaniasis: public health aspects and control. Clin Dermatol 1996; 14: 417–23PubMedCrossRefGoogle Scholar
  91. 91.
    Uzun S, Uslular C, Yucel A, et al. Cutaneous leishmaniasis: evaluation of 3,074 cases in the Cukurova region of Turkey. Br J Dermatol 1999; 140: 347–50PubMedCrossRefGoogle Scholar
  92. 92.
    Rowland M, Munir A, Durrani N,et al. An outbreak of cutaneous leishmaniasis in an Afghan refugee settlement in north-west Pakistan. Trans R Soc Trop Med Hyg 1999; 93: 133–6PubMedCrossRefGoogle Scholar
  93. 93.
    Brooker S, Mohammed N, Adil K, et al. Leishmaniasis in refugee and local Pakistani populations. Emerg Infect Dis 2004; 10: 1681–4PubMedCrossRefGoogle Scholar
  94. 94.
    Cupolillo E, Aguiar AF, Brahim LR, et al. Recent advances in the taxonomy of the New World leishmanial parasites. Med Microbiol Immunol (Berl) 2001; 190: 57–60Google Scholar
  95. 95.
    Cupolillo E, Brahim LR, Toaldo CB, et al. Genetic polymorphism and molecular epidemiology of Leishmania (Viannia) braziliensis from different hosts and geographic areas in Brazil. J Clin Microbiol 2003; 41: 3126–32PubMedCrossRefGoogle Scholar
  96. 96.
    Marfurt J, Niederwieser I, Makia ND,et al. Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP. Diagn Microbiol Infect Dis 2003; 46: 115–24PubMedCrossRefGoogle Scholar
  97. 97.
    Cupolillo E, Momen H, Grimaldi Jr G. Genetic diversity in natural populations of New World Leishmania. Mem Inst Oswaldo Cruz 1998; 93: 663–8PubMedCrossRefGoogle Scholar
  98. 98.
    Lainson R, Shaw JJ. The laboratory mix-up of Leishmania strains [letter]. Trans R Soc Trop Med Hyg 1990; 84: 753PubMedCrossRefGoogle Scholar
  99. 99.
    Shaw JJ. Taxonomy of the genus Leishmania: present and future trends and their implications. Mem Inst Oswaldo Cruz 1994; 89: 471–8PubMedCrossRefGoogle Scholar
  100. 100.
    Rioux JA, Lanotte G, Serres E,et al. Taxonomy of Leishmania: use of isoenzymes. Suggestions for a new classification. Ann Parasitol Hum Comp 1990; 65: 111–25PubMedGoogle Scholar
  101. 101.
    Killick-Kendrick R. Phlebotomine vectors of the leishmaniases: a review. Med Vet Entomol 1990; 4: 1–24PubMedCrossRefGoogle Scholar
  102. 102.
    Killick-Kendrick R. The biology and control of phlebotomine sand flies. Clin Dermatol 1999; 17: 279–89PubMedCrossRefGoogle Scholar
  103. 103.
    Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27: 305–18PubMedCrossRefGoogle Scholar
  104. 104.
    Bauer IL. Knowledge and behavior of tourists to Manu National Park, Peru, in relation to leishmaniasis. J Travel Med 2002; 9: 173–9PubMedCrossRefGoogle Scholar
  105. 105.
    El Hajj L, Thellier M, Carriere J,et al. Localized cutaneous leishmaniasis imported into Paris: a review of 39 cases. Int J Dermatol 2004; 43: 120–5PubMedCrossRefGoogle Scholar
  106. 106.
    Harms G, Schonian G, Feldmeier H. Leishmaniasis in Germany. Emerg Infect Dis 2003; 9: 872–5PubMedCrossRefGoogle Scholar
  107. 107.
    Schwartz E, Hatz C, Blum J. New World cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006; 6: 342–9PubMedCrossRefGoogle Scholar
  108. 108.
    Guiguemde RT, Sawadogo OS, Bories C, et al. Leishmania major and HIV co-infection in Burkina Faso. Trans R Soc Trop Med Hyg 2003; 97: 168–9PubMedCrossRefGoogle Scholar
  109. 109.
    Maingon RD, Ward RD, Hamilton JG,et al. The Lutzomyia longipalpis species complex: does population sub-structure matter to leishmania transmission? Trends Parasitol 2008 Jan; 24 (1): 12–7PubMedCrossRefGoogle Scholar
  110. 110.
    Uthman MA, Satir AA, Tabbara KS. Clinical and histopathological features of zoonotic cutaneous leishmaniasis in Saudi Arabia. J Eur Acad Dermatol Venereol 2005; 19: 431–6PubMedCrossRefGoogle Scholar
  111. 111.
    Jacobson RL, Eisenberger CL, Svobodova M,et al. Outbreak of cutaneous leish-maniasis in northern Israel. J Infect Dis 2003; 188: 1065–73PubMedCrossRefGoogle Scholar
  112. 112.
    Al Tawfiq JA, AbuKhamsin A. Cutaneous leishmaniasis: a 46-year study of the epidemiology and clinical features in Saudi Arabia (1956-2002). Int J Infect Dis 2004; 8: 244–50CrossRefGoogle Scholar
  113. 113.
    Sharma NL, Mahajan VK, Kanga A,et al. Localized cutaneous leishmaniasis due to Leishmania donovani and Leishmania tropica: preliminary findings of the study of 161 new cases from a new endemic focus in Himachal Pradesh, India. Am J Trop Med Hyg 2005; 72: 819–24PubMedGoogle Scholar
  114. 114.
    Barnetson RS, Ridley RS, Wheate HW. A form of muco-cutaneous leishmaniasis in the Old World. Trans R Soc Trop Med Hyg 1978; 72: 516–8PubMedCrossRefGoogle Scholar
  115. 115.
    Morsy TA, Khalil NM, Salama MM,et al. Mucosal leishmaniasis caused by Leishmania tropica in Saudi Arabia. J Egypt Soc Parasitol 1995; 25: 73–9PubMedGoogle Scholar
  116. 116.
    Oliveira CC, Lacerda HG, Martins DR,et al. Changing epidemiology of American cutaneous leishmaniasis (ACL) in Brazil: a disease of the urban-rural interface. Acta Trop 2004; 90: 155–62PubMedCrossRefGoogle Scholar
  117. 117.
    Romero GA, Ishikawa E, Cupolillo E,et al. The rarity of infection with Leishmania (Viannia) braziliensis among patients from the Manaus region of Amazonas state, Brazil, who have cutaneous leishmaniasis. Ann Trop Med Parasitol 2002; 96: 131–6PubMedCrossRefGoogle Scholar
  118. 118.
    Corredor A, Kreutzer RD, Tesh RB,et al. Distribution and etiology of leishmaniasis in Colombia. Am J Trop Med Hyg 1990; 42: 206–14PubMedGoogle Scholar
  119. 119.
    Velez I, Agudelo S, Robledo S,et al. Diffuse cutaneous leishmaniasis with mucosal involvement in Colombia, caused by an enzymatic variant of Leishmania panamensis. Trans R Soc Trop Med Hyg 1994; 88: 199PubMedCrossRefGoogle Scholar
  120. 120.
    Turetz ML, Machado PR, Ko AI,et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 2002; 186: 1829–34PubMedCrossRefGoogle Scholar
  121. 121.
    Silveira FT, Lainson R, Corbett CE. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz 2004; 99: 239–51PubMedCrossRefGoogle Scholar
  122. 122.
    Silveira FT, Lainson R, Corbett CE. Further observations on clinical, histopathological, and immunological features of borderline disseminated cutaneous leishmaniasis caused by Leishmania (Leishmania) amazonensis. Mem Inst Oswaldo Cruz 2005; 100: 525–34PubMedCrossRefGoogle Scholar
  123. 123.
    Reithinger R, Aadil K, Hami S,et al. Cutaneous leishmaniasis, northern Afghanistan. Emerg Infect Dis 2004; 10: 966–7PubMedCrossRefGoogle Scholar
  124. 124.
    Magill AJ. Epidemiology of the leishmaniases. Dermatol Clin 1995; 13: 505–23PubMedGoogle Scholar
  125. 125.
    Navin TR, Arana FE, de Merida AM,et al. Cutaneous leishmaniasis in Guatemala: comparison of diagnostic methods. Am J Trop Med Hyg 1990; 42: 36–42PubMedGoogle Scholar
  126. 126.
    De Bruijn MH, Barker DC. Diagnosis of New World leishmaniasis: specific detection of species of the Leishmania braziliensis complex by amplification of kinetoplast DNA. Acta Trop 1992; 52: 45–58PubMedCrossRefGoogle Scholar
  127. 127.
    Weigle KA, de Davalos M, Heredia P,et al. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am J Trop Med Hyg 1987; 36: 489–96PubMedGoogle Scholar
  128. 128.
    Kalter DC. Laboratory tests for the diagnosis and evaluation of leishmaniasis. Dermatol Clin 1994; 12: 37–50PubMedGoogle Scholar
  129. 129.
    Faber WR, Oskam L, van Gool T,et al. Value of diagnostic techniques for cutaneous leishmaniasis. J Am Acad Dermatol 2003; 49: 70–4PubMedCrossRefGoogle Scholar
  130. 130.
    Sarantopoulos GP, Binder S, Wortmann G,et al. Old World cutaneous leishmaniasis in Los Angeles: a case report, overview of the current literature, and guide for the treating dermatopathologist. Am J Dermatopathol 2003; 25: 321–6PubMedCrossRefGoogle Scholar
  131. 131.
    Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46: 296–306PubMedGoogle Scholar
  132. 132.
    World Health Organization. The leishmaniases. WHO technical report series. Vol 701. Geneva: WHO, 1984Google Scholar
  133. 133.
    Romero GA, Guerra MV, Paes MG,et al. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001; 65: 456–65PubMedGoogle Scholar
  134. 134.
    Oliveira-Neto MP, Schubach A, Mattos M,et al. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathol Biol (Paris) 1997; 45: 496–9Google Scholar
  135. 135.
    Oliveira-Neto MP, Schubach A, Mattos M,et al. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil: an area of Leishmania (V.) braziliensis transmission. Int J Dermatol 1997; 36: 463–8PubMedCrossRefGoogle Scholar
  136. 136.
    Blum J, Desjeux P, Schwartz E,et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004; 53: 158–66PubMedCrossRefGoogle Scholar
  137. 137.
    Lai A Fat EJ, Vrede MA, Soetosenojo RM,et al. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol 2002; 41: 796–800CrossRefGoogle Scholar
  138. 138.
    Tuon FF, Amato VS, Graf ME,et al. Treatment of New World cutaneous leishmaniasis: a systematic review with a meta-analysis. Int J Dermatol 2008 Feb; 47 (2): 109–24PubMedCrossRefGoogle Scholar
  139. 139.
    Soto J, Rea J, Balderrama M,et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008 Feb; 78 (2): 210–1PubMedGoogle Scholar
  140. 140.
    Berman J. Miltefosine to treat leishmaniasis. Expert Opin Pharmacother 2005; 6: 1381–8PubMedCrossRefGoogle Scholar
  141. 141.
    Soto J, Soto P. Miltefosine: oral treatment of leishmaniasis. Expert Rev Anti Infect Ther 2006; 4: 177–85PubMedCrossRefGoogle Scholar
  142. 142.
    Soto J, Toledo J, Valda L,et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44: 350–6PubMedCrossRefGoogle Scholar
  143. 143.
    El Safi SH, Murphy AG, Bryceson AD,et al. A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment. Trans R Soc Trop Med Hyg 1990; 84: 690–1PubMedCrossRefGoogle Scholar
  144. 144.
    El On J, Halevy S, Grunwald MH,et al. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992; 27: 227–31PubMedCrossRefGoogle Scholar
  145. 145.
    Gurei MS, Tatli N, Ozbilge H,et al. Efficacy of cryotherapy and intralesional Pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol 2000; 30: 169–76PubMedGoogle Scholar
  146. 146.
    Faris RM, Jarallah JS, Khoja TA,et al. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol 1993; 32: 610–2PubMedCrossRefGoogle Scholar
  147. 147.
    Asilian A, Sadeghinia A, Faghihi G,et al. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43: 281–3PubMedCrossRefGoogle Scholar
  148. 148.
    Alrajhi AA, Ibrahim EA, De Vol EB,et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346: 891–5PubMedCrossRefGoogle Scholar
  149. 149.
    Weinrauch L, Livshin R, El On J. Ketoconazole in cutaneous leishmaniasis. Br J Dermatol 1987; 117: 666–8PubMedCrossRefGoogle Scholar
  150. 150.
    Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis 2007 May; 5 (3): 150–8PubMedCrossRefGoogle Scholar
  151. 151.
    Reithinger R, Mohsen M, Wahid M,et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 2005; 40: 1148–55PubMedCrossRefGoogle Scholar
  152. 152.
    De Araujo T, Marques AC, Kerdel F. Sporotrichosis. Int J Dermatol 2001; 40: 737–42PubMedCrossRefGoogle Scholar
  153. 153.
    Barros MB, Schubach AO, do Valle AC, et al. Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin Infect Dis 2004; 38: 529–35PubMedCrossRefGoogle Scholar
  154. 154.
    Schubach A, Schubach TM, Barros MB, et al. Cat-transmitted sporotrichosis, Rio de Janeiro, Brazil. SEmerg Infect Dis 2005; 11: 1952–4CrossRefGoogle Scholar
  155. 155.
    da Rosa AC, Scroferneker ML, Vettorato R, et al. Epidemiology of sporotrichosis: a study of 304 cases in Brazil. J Am Acad Dermatol 2005; 52: 451–9PubMedCrossRefGoogle Scholar
  156. 156.
    Neyra E, Fonteyne PA, Swinne D, et al. Epidemiology of human sporotrichosis investigated by amplified fragment length polymorphism. J Clin Microbiol 2005; 43: 1348–52PubMedCrossRefGoogle Scholar
  157. 157.
    Bustamante B, Campos PE. Endemic sporotrichosis. Curr Opin Infect Dis 2001; 14: 145–9PubMedCrossRefGoogle Scholar
  158. 158.
    Quintal D. Sporotrichosis infection on mines of the Witwatersrand. J Cutan Med Surg 2000; 4: 51–4PubMedGoogle Scholar
  159. 159.
    Werner AH, Werner BE. Sporotrichosis in man and animal. Int J Dermatol 1994; 33: 692–700PubMedCrossRefGoogle Scholar
  160. 160.
    Carvalho MT, de Castro AP, Baby C, et al. Disseminated cutaneous sporotrichosis in a patient with AIDS: report of a case. Rev Soc Bras Med Trop 2002; 35: 655–9PubMedCrossRefGoogle Scholar
  161. 161.
    Bullpitt P, Weedon D. Sporotrichosis: a review of 39 cases. Pathology 1978; 10: 249–56PubMedCrossRefGoogle Scholar
  162. 162.
    Winn RE, Anderson J, Piper J, et al. Systemic sporotrichosis treated with itraconazole. Clin Infect Dis 1993; 17: 210–7PubMedCrossRefGoogle Scholar
  163. 163.
    Conti Diaz IA, Civila E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992; 35: 153–6Google Scholar
  164. 164.
    Chapman SW, Pappas P, Kauffmann C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 2004; 47: 62–8PubMedCrossRefGoogle Scholar
  165. 165.
    Cabezas C, Bustamante B, Holgado W, et al. Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide. Pediatr Infect Dis J 1996; 15: 352–4PubMedCrossRefGoogle Scholar
  166. 166.
    Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis 1995; 21: 981–5PubMedCrossRefGoogle Scholar
  167. 167.
    Bonifaz A, Carrasco-Gerard E, Saul A. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses 2001; 44: 1–7PubMedCrossRefGoogle Scholar
  168. 168.
    Lupi O, Tyring SK, McGinnis MR. Tropical dermatology: fungal tropical diseases. J Am Acad DermatolS 2005; 53: 931–51, quizPubMedCrossRefGoogle Scholar
  169. 169.
    Rivitti EA, Aoki V. Deep fungal infections in tropical countries. SClin Dermatol 1999; 17: 171–90CrossRefGoogle Scholar
  170. 170.
    Howles JK, Kennedy CB, Garvin WH, et al. Chromoblastomycosis: report of nine cases from a single area in Louisiana. AMA Arch Derm Syphilol 1954; 69: 83–90PubMedCrossRefGoogle Scholar
  171. 171.
    Bonifaz A, Paredes-Solis V, Saul A. Treating chromoblastomycosis with systemic antifungals. SExpert Opin Pharmacother 2004; 5: 247–54CrossRefGoogle Scholar
  172. 172.
    Magana M, Magana-Garcia M. Mycetoma. Dermatol Clin 1989; 7: 203–17PubMedGoogle Scholar
  173. 173.
    McGinnis MR. Mycetoma. Dermatol Clin 1996; 14: 97–104PubMedCrossRefGoogle Scholar
  174. 174.
    Lichon V, Khachemoune A. Mycetoma: a review. Am J Clin Dermatol 2006; 7: 315–21PubMedCrossRefGoogle Scholar
  175. 175.
    Fahal AH. Mycetoma: a thorn in the flesh. Trans R Soc Trop Med Hyg 2004; 98: 3–11PubMedCrossRefGoogle Scholar
  176. 176.
    Fahal AH, Sharfi AR, Sheik HE, et al. Internal fistula formation: an unusual complication of mycetoma. Trans R Soc Trop Med Hyg 1996; 90: 550–2PubMedCrossRefGoogle Scholar
  177. 177.
    Fahal AH, Hassan MA. Mycetoma. Br J Surg 1992; 79: 1138–41PubMedCrossRefGoogle Scholar
  178. 178.
    Welsh O, Salinas MC, Rodriguez MA. Treatment of eumycetoma and actino- mycetoma. Curr Top Med Mycol 1995; 6: 47–71PubMedGoogle Scholar
  179. 179.
    Welsh O. Mycetoma: current concepts in treatment. Int J Dermatol 1991; 30: 387–98PubMedCrossRefGoogle Scholar
  180. 180.
    Bonifaz A, Flores P, Saul A, et al. Treatment of actinomycetoma due to Nocardia spp. with amoxicillin-clavulanate. Br J Dermatol 2007; 156: 308–11PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Department of DermatologyAcademic Medical CentreAmsterdamthe Netherlands
  2. 2.Department of DermatologyFlevoziekenhuisAlmerethe Netherlands

Personalised recommendations